FierceBiotech

Vertex inches closer to acute pain market with FDA application acceptance

Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor ...
FierceBiotech

Vertex's pain prospect hits main goal in phase 3 trials but fails to beat Vicodin

Vertex’s long-running attempt to crack the blockbuster pain market has finally delivered a pair of phase 3 wins. And yet, the positive news was tempered by the failure to hit key secondary endpoints ...
Reuters

US FDA approves Vertex's non-opioid painkiller

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...
Bloomberg L.P.

Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...